Research Nester released a report titled “Dementia and Alzheimer’s Disease Treatment Market: Global Demand Analysis & Opportunity Outlook 2028” which delivers detailed overview of the global dementia and Alzheimer’s disease treatment market in terms of market segmentation by drug class, by distribution channel, and by region.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.
As per the World Health Organization, around 50 million people have dementia globally. The number of cases increases by nearly 10 million annually. The most common form of dementia is Alzheimer’s disease, which constitutes of about 60-70% of the total cases.
The dementia and Alzheimer’s disease treatment market is anticipated to record a notable CAGR over the forecast period, i.e., 2020-2028. The market is segmented by drug class, by distribution channel and by region, out of which, the drug class segment is further segmented into cholinesterase inhibitors, memantine and combination drugs (memantine and donepezil). Based on this, the segment for cholinesterase inhibitors is anticipated to observe significantly high growth which can be attributed to the increased use of Alzheimer’s medications such as donepezil, galantamine and rivastigmine.
On the basis of regional analysis, the dementia and Alzheimer’s disease treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America is anticipated to hold a large share as the expenditure on healthcare is estimated to increase by a significant amount in North America along with the growing cases of Alzheimer’s disease. The dementia and Alzheimer’s treatment market in Asia Pacific region is anticipated to grow at the highest rate over the forecast period on the back of rising research and development activities in the region.
Rising Awareness among Patients about the Disorder to Boost the Market Growth
According to statistics released by the Alzheimer’s Association in 2020, an estimated 5.8 million people above the age of 65 in America are living with Alzheimer’s disease. This number is further predicted to increase to 13.8 million people above the age of 65 by 2050.
The growing number of cases among the elderly people is estimated to increase the demand for effective treatment method, thereby resulting in growth of the dementia and Alzheimer’s disease treatment market over the forecast period. However, the side effects linked with the use of these drugs such as nausea, insomnia, diarrhea, fatigue and anorexia are estimated to restrict the growth of market.
This report also provides the existing competitive scenario of some of the key players of the global dementia and Alzheimer’s disease treatment market which includes company profiling of Novartis AG (SWX: NOVN), Pfizer, Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Allergan plc (NYSE: AGN), Eli Lilly and Company (NYSE: LLY), F. Hoffmann-La Roche Ltd. (SWX: RO), AstraZeneca (LON: AZN), Biogen (NASDAQ: BIIB), Eisai Co., Ltd. (TYO: 4523) and INmuneBIO (NASDAQ: INMB). The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global dementia and Alzheimer’s disease treatment market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.
Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment, etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.
U.S. Phone: [+1 646 586 9123]
U.K. Phone: [+44 203 608 591]